Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Booster immunotherapy (BIT)

C Ebner1, D Kraft, H Ebner

  • 1Institute of General and Experimental Pathology, University of Vienna, Austria.

Allergy
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An uncommon case of POLE mutated uterine carcinosarcoma - complemented by a review of literature.

Gynecologic oncology reports·2024
Same author

Evaluation of 'implications for research' statements in systematic reviews of interventions in advanced cancer patients - a meta-research study.

BMC medical research methodology·2023
Same author

When and how do patients with cardiac amyloidosis die?

Clinical research in cardiology : official journal of the German Cardiac Society·2019
Same author

Distinct epitope structures of defensin-like proteins linked to proline-rich regions give rise to differences in their allergenic activity.

Allergy·2017
Same author

Amb a 1 isoforms: Unequal siblings with distinct immunological features.

Allergy·2017
Same author

Influence of the Ag concentration on the medium-range order in a CuZrAlAg bulk metallic glass.

Scientific reports·2017
Same journal

Deficiency of Mitochondrial Fatty Acid Enzyme, CPT1A, Underlies Airway Epithelial Barrier Dysfunction in Severe Asthma.

Allergy·2026
Same journal

Surgical Management of Non-Allergic Rhinitis-An EAACI Task Force Position Paper.

Allergy·2026
Same journal

Real-World Evaluation of AI-Assisted Readout of Skin Prick Automated Test Results.

Allergy·2026
Same journal

Serotonin Degradation and Lipid Metabolism Regulate Human Tc2 Cell Effector Functions.

Allergy·2026
Same journal

Protein Corona-Coated Crystal Silica From Sandstorms Amplifies Allergic Rhinitis by Regulating Epithelial Integrity in Mice and Human Nasal Epithelia.

Allergy·2026
Same journal

EAACI Guidelines on Environmental Science for Allergy and Asthma-Evidence-Based Recommendations for Prevention and Public Health Action to Mitigate the Impact of Pollen Exposure on Respiratory Allergy.

Allergy·2026
See all related articles

Successful immunotherapy for grass/rye pollen allergy offers lasting effects, with relapse risk decreasing after three years. Booster immunotherapy (BIT) effectively manages recurring symptoms in allergic patients.

Area of Science:

  • Allergy and Immunology
  • Clinical Therapeutics

Background:

  • Pollen allergy immunotherapy (IT) is a common treatment.
  • Long-term efficacy and management of relapsed cases require further investigation.

Purpose of the Study:

  • To determine the duration of therapeutic effects after discontinuing immunotherapy.
  • To evaluate the effectiveness of booster immunotherapy (BIT) for patients experiencing symptom recurrence.

Main Methods:

  • A questionnaire assessed symptom relapse in 108 patients after completing 3-4 years of IT.
  • A clinical study evaluated BIT in 40 patients with recurrent grass/rye pollen allergy symptoms.

Main Results:

  • Approximately 30% of patients experienced symptom recurrence within the first three years post-IT.

Related Experiment Videos

  • Booster immunotherapy (BIT) led to significant symptom improvement or remission in 70% of patients during the subsequent pollen season.

    • Conclusions:

    • The risk of relapse appears low after three years of sustained remission.
    • Booster immunotherapy (BIT) is an effective treatment option for managing recurrent pollen allergy symptoms after initial immunotherapy.